Ionis therapeutics stock
Web30 mrt. 2024 · On this news, Ionis's stock price fell $12.05 per share, or 21.66%, ... SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of … WebIn May 2016, Ionis licensed the rights to the drug to Kastle Therapeutics for $15 million upfront with another $10 million due in May 2024, up to $70 million in milestones based …
Ionis therapeutics stock
Did you know?
WebCompany. Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company is primarily focused on cardiovascular … Web30 mrt. 2024 · On this news, Ionis's stock price fell $12.05 per share, or 21.66%, to close at $43.59 per share on March 23, 2024. The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris...
Web13 apr. 2024 · The company’s stock has been forecasted to trade at an average price of $8.32 over the course of the next 52 weeks, with a low of $4.00 and a high of $16.00. Based on these price targets, the low is 28.7% off current price, whereas the price has to move -185.2% to reach the yearly target high. Web1 sep. 2024 · Ionis Pharmaceuticals has agreed to purchase the remaining outstanding shares in Akcea Therapeutics for a total cash consideration of about $500m, or $18.15 per share. Ionis expects to benefit via financial upside from Akcea’s pipeline and commercial medicines. Credit: Ionis Pharmaceuticals.
Web11 apr. 2024 · Discover historical prices for IONS stock on Yahoo Finance. View daily, weekly or monthly format back to when Ionis Pharmaceuticals, Inc. stock was issued. WebLegal Name Ionis Pharmaceuticals, Inc. Stock Symbol NASDAQ:IONS Company Type For Profit Phone Number (760)931-9200 Ionis Pharmaceuticals is a pharmaceutical company. It specializes in RNA-targeted drug discovery and development.
WebIonis Pharmaceuticals, Inc. University of California, Irvine Activity Congratulations to #Ionis CSO C. Frank Bennett, Ph.D., co-recipient of the Rainwater Prize for Outstanding Innovation in...
Web27 mrt. 2024 · Ionis Pharmaceuticals Inc’s stock is NA in 2024, NA in the previous five trading days and up 4.88% in the past year. Currently, Ionis Pharmaceuticals Inc does not have a price-earnings ratio. Ionis Pharmaceuticals Inc’s trailing 12-month revenue is $587.4 million with a -45.9% net profit margin. philhealth employees premium remittance listWeb28 mrt. 2024 · For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading cardiovascular and neurological franchises. philhealth employer due dateWeb13 jul. 2024 · For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three... philhealth employee shareWebProQR receives exclusive worldwide license for IONIS-RHO-2.5 Rx, now QR-1123, for autosomal dominant retinitis pigmentosa ... trial in adRP patients is expected to start in … philhealth employer contribution calculatorWebIonis Pharmaceuticals Inc Follow Share $37.23 After Hours: $37.23 (0.00%) 0.00 Closed: Apr 11, 7:29:48 PM GMT-4 · USD · NASDAQ · Disclaimer search Compare to Crispr … philhealth employerWeb16 mrt. 2024 · Ionis Pharmaceuticals Inc : Entry into a Material Definitive Agreement, Financial Statemen.. 04/01: Biogen, Alcyone Therapeutics to Collaborate on Medical … philhealth employer contribution 2023WebIonis Pharmaceuticals, Inc. Common Stock (IONS) Pre-Market Quotes Nasdaq Pre-Market: IONS Edit my quotes Ionis Pharmaceuticals, Inc. Common Stock (IONS) … philhealth employer change password